Obesity Drug Shows Promising Results for Children Aged 6-11
Translated & summarized from Arutz Sheva by baba
A new study indicates the obesity drug Wegovy is effective for children aged 6-11, with about 40% no longer classified as obese after 68 weeks of treatment. The drug showed a 17.4% average BMI reduction in participants, who also received lifestyle counseling. While no growth impairment was noted, common side effects like nausea and diarrhea occurred. Novo Nordisk will seek FDA approval to extend its use to this younger age group.
The story in 5 lines · by baba
- Wegovy treatment led to 40% of severely obese children exiting the medical definition of obesity.
- Children aged 6-11 saw an average 17.4% reduction in body mass index with Wegovy.
- The study involved 165 children and was published in the New England Journal of Medicine.
- Three Israeli medical centers participated in the Wegovy obesity drug trial.
- Novo Nordisk plans to seek FDA approval for Wegovy's use in younger children.
A new study on the drug Wegovy, manufactured by Novo Nordisk, has demonstrated significant success in treating severe obesity in children aged 6 to 11. The research, published in the New England Journal of Medicine, involved 165 children who received weekly injections of semaglutide, the active ingredient in Wegovy, or a placebo, alongside nutritional and exercise guidance. After 68 weeks, children treated with Wegovy experienced an average 17.4% reduction in their body mass index (BMI), while those in the placebo group saw a 2.2% increase. Notably, approximately 40% of children who completed the Wegovy treatment no longer met the medical definition of obesity, a result not achieved by any child in the control group. The study also indicated that 83% of children on Wegovy showed BMI improvement compared to 23.5% in the placebo group. The participants were severely obese, with most classified as having Class 3 and 4 obesity, equivalent to adult BMI levels of 35 and 45, respectively, which carry increased health risks. Novo Nordisk reported that the drug did not impede the growth or development of the children during the study period. However, common side effects such as nausea, diarrhea, vomiting, abdominal pain, gas, heartburn, and hair loss were observed, similar to those seen in adolescent and adult users. Three Israeli medical centers participated in the trial: Schneider Children's Medical Center, Shamir Medical Center, and Rambam Medical Center. Based on these findings, Novo Nordisk plans to seek FDA approval to expand Wegovy's use to children aged 6 to 11 suffering from obesity, as it is currently approved only for those aged 12 and older.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 2Right 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
